Breaux/Frist Medicare Board Is One Sore Spot In Rx Firms' Favored Bill
Executive Summary
A federal Medicare Board will likely be one of the most sensitive issues for the brand name pharmaceutical industry in deciding how enthusiastically to support Medicare reform legislation introduced Nov. 9 by Sens. Breaux (D-La.), Frist (R-Tenn.), Kerrey (D-Neb.) and Hagel (R-Neb.).
You may also be interested in...
AARP Prepared To Block Medicare Reform Plans That Do Not Meet Standards
AARP is prepared to mobilize its membership to block any Medicare reform legislation that is rushed through Congress without adequate consideration for its impact on beneficiaries, according to testimony given to the Senate Special Committee on Aging Feb. 8 by AARP board member Beatrice Braun, MD.
AARP Prepared To Block Medicare Reform Plans That Do Not Meet Standards
AARP is prepared to mobilize its membership to block any Medicare reform legislation that is rushed through Congress without adequate consideration for its impact on beneficiaries, according to testimony given to the Senate Special Committee on Aging Feb. 8 by AARP board member Beatrice Braun, MD.
Clinton Medicare Rx Benefit To Add Medical Error Reduction Component
President Clinton's updated Medicare drug benefit proposal for 2000 will highlight the importance of reducing clinical errors, Office of Management & Budget Associate Director-Health and Personnel Daniel Mendelson told the National Congress on the Future of Pharmaceuticals in Medical Care Dec. 9 in Washington, D.C.